Syverson Strege & CO Eli Lilly & CO Transaction History

Syverson Strege & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$724.87 - $909.04 $98,582 - $123,629	136 Added 40.36%	473 $428,000
Q1 2024 Apr 30, 2024	BUY	$592.2 - $792.28 $199,571 - $266,998	337 New	337 $262,000
Q1 2023 May 03, 2023	BUY	$310.63 - $364.82 $26,092 - $30,644	84 Added 25.45%	414 $142,000
Q4 2021 Jan 19, 2022	SELL	$224.85 - $279.04 $26,982 - $33,484	-120 Reduced 26.67%	330 $91,000
Q3 2021 Nov 02, 2021	BUY	$221.6 - $272.71 $26,592 - $32,725	120 Added 36.36%	450 $104,000
Q4 2020 Feb 03, 2021	BUY	$130.46 - $172.63 $43,051 - $56,967	330 New	330 $56,000

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Syverson Strege & CO, based on Form 13F filings with the SEC.

Stay updated on Syverson Strege & CO with notifications on news.